Ruthenium compounds as anticancer agents
New ruthenium-based compounds with fewer and less severe side effects, could replace longstanding platinum-based anticancer drugs
For half a century, the field of metal-based anticancer drugs has been dominated by the precious metal platinum. The discovery of platinum's anticancer properties was made by chance during an experiment in 1965, conducted at Michigan State University by Barnett Rosenberg. Rosenberg used a platinum electrode to apply an electric field to a colony of E. coli, which was observed to inhibit their growth. A diligent investigation into the cause of this effect concluded that the platinum electrode was breaking down to generate platinum(II) species in situ, which was stopping the cells from multiplying.
This observation led to cis-diamminedichloroplatinum(II), commonly known as cisplatin, being approved by the American Food and Drugs Administration (FDA) for cancer therapy in 1978. It has since become the most widely used anticancer drug, with an estimated 70% of patients receiving the compound as part of their treatment.1
Thanks for using Education in Chemistry. You can view one Education in Chemistry article per month as a visitor.
Register for Teach Chemistry for free, unlimited access
Registration is open to all teachers and technicians at secondary schools, colleges and teacher training institutions in the UK and Ireland.
Get all this, plus much more:
- unlimited access to resources, core practical videos and Education in Chemistry articles
- teacher well-being toolkit, personal development resources and online assessments
- applications for funding to support your lessons
Already a Teach Chemistry member? Sign in now.
Not eligible for Teach Chemistry? Sign up for a personal account instead, or you can also access all our resources with Royal Society of Chemistry membership.